Altman Peter 4

What Happened

• Peter Altman, President & CEO and a Director of BioCardia, was reported as the recipient of 110,625 restricted stock units (RSUs) on June 29, 2026. The RSUs are reported at an acquisition price of $1.20 per share, for a total reported value of $132,750. The filing records this transaction as an award/grant (transaction code A) and notes that 100% of the RSUs vested on June 29, 2026.

Key Details

• Transaction date: June 29, 2026; Form 4 filed: July 1, 2026 (timely — Form 4 typically due within two business days).
• Security: 110,625 RSUs, reported acquisition price $1.20 per share; total reported value $132,750.
• Footnote: RSUs represent a contingent right to receive one share of common stock; 100% vested on June 29, 2026.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction code: A (award/grant). No 10b5-1, tax-withholding, or sale reported in the excerpt.

Context

• RSUs are compensation awards that convert to shares upon vesting; this report documents vesting/acquisition rather than an open-market buy or sale. Such awards reflect compensation, not necessarily a direct market sentiment signal. The filing appears timely (filed 2 days after the reported vesting/acquisition).